Absci Advances AI-Designed Antibody ABS-201 into Phase 2 Trial for Endometriosis
Event summary
- Absci plans to initiate a global, multi-center Phase 2 trial for ABS-201, an AI-designed anti-prolactin receptor antibody, in mid-2027.
- The trial will assess efficacy and safety in 150 patients with surgically-diagnosed endometriosis and moderate to severe pain.
- ABS-201 is designed using Absci’s generative AI platform, offering a non-hormonal approach to endometriosis treatment.
- Dose levels for the Phase 2 trial will be determined based on data from the ongoing HEADLINE trial for pattern hair loss.
The big picture
Absci’s advancement of ABS-201 into Phase 2 trials underscores the growing role of AI in drug discovery, particularly for conditions with limited treatment options. The non-hormonal approach to endometriosis aligns with broader industry trends toward targeted therapies with differentiated safety profiles. Success in this trial could position ABS-201 as a potential best-in-class therapeutic in a market affecting roughly one in ten women of reproductive age.
What we're watching
- Clinical Efficacy
- Whether ABS-201 can demonstrate significant reductions in endometriosis-associated pain compared to placebo.
- Regulatory Timelines
- The pace at which Absci secures regulatory clearance for the Phase 2 trial initiation in mid-2027.
- Market Potential
- The commercial prospects of ABS-201 in a market with substantial unmet medical need for non-hormonal endometriosis treatments.
Related topics